Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Nutrition
Published in: European Journal of Nutrition 3/2016

01-04-2016 | Original Contribution

Multiplatform metabolomic fingerprinting as a tool for understanding hypercholesterolemia in Wistar rats

Authors: Diana González-Peña, Danuta Dudzik, Clara Colina-Coca, Begoña de Ancos, Antonia García, Coral Barbas, Concepción Sánchez-Moreno

Published in: European Journal of Nutrition | Issue 3/2016

Login to get access

Abstract

Purpose

The aim was to investigate the impact of hypercholesterolemic diet on the metabolome of male Wistar rats by a multiplatform metabolomic fingerprinting.

Methods

Male Wistar rats were fed with two different diets [control (C) and high-cholesterol diet (HC)—containing 2 % cholesterol and 0.5 % cholic acid]. After 7 weeks of experimental feeding, the rats were euthanized for blood collection and plasma recovery. The metabolite fingerprint was then achieved by applying a multiplatform comprising LC–MS, GC–MS and CE–MS.

Results

Multivariate statistical analysis showed a clear separation between the C and HC groups. Individual differences in metabolites were evaluated using univariate statistical analysis, and multiple metabolites were identified and confirmed in the plasma. A global profiling integrates for the first time pathways affected by high-cholesterol diet intake and allowed us to elucidate some of the associated alterations underlying the hypercholesterolemia event in Wistar rats.

Conclusions

HC feeding stimulated the alteration of multiple pathways in Wistar rats, warning of the risk of developing important diseases, which can be modulated by the diet. Further studies are required to investigate the possibilities to revert or ameliorate the negative effects triggered by HC intake.
Literature
1.
Nichols M, Townsend N, Scarborough P, Rayner M (2013) Cardiovascular disease in Europe: epidemiological update. Eur Heart J 34:3028–3034CrossRef
2.
Artham SM, Lavie CJ, De Schutter A, Ventura HO, Milani RV (2011) Obesity, age, and cardiac risk. Curr Cardiovasc Risk Rep 5:128–137CrossRef
3.
Sherzai A, Heim LT, Boothby C, Sherzai AD (2012) Stroke, food groups, and dietary patterns: a systematic review. Nutr Rev 70:423–435CrossRef
4.
Andersen CJ, Fernandez ML (2013) Dietary strategies to reduce metabolic syndrome. Rev Endocr Metab Disord 14:241–254CrossRef
5.
van Baak MA (2013) Nutrition as a link between obesity and cardiovascular disease: how can we stop the obesity epidemic? Thromb Haemost 110:689–696CrossRef
6.
Grosso G, Mistretta A, Frigiola A, Gruttadauria S, Biondi A, Basile F, Vitaglione P, D’Orazio N, Galvano F (2014) Mediterranean diet and cardiovascular risk factors: a systematic review. Crit Rev Food Sci Nutr 54:593–610CrossRef
7.
Nascimento AR, Machado M, De Jesus N, Gomes F, Lessa MA, Bonomo IT, Tibiriçá E (2013) Structural and functional microvascular alterations in a rat model of metabolic syndrome induced by a high-fat diet. Obesity 21:2046–2054CrossRef
8.
McEvoy CT, Neville CE, Temple NJ, Woodside JV (2014) Effect of diet on vascular health. Rev Clin Gerontol 24:25–40CrossRef
9.
Neuhofer A, Wernly B, Leitner L, Sarabi A, Sommer NG, Staffler G, Zeyda M, Stulnig TM (2014) An accelerated mouse model for atherosclerosis and adipose tissue inflammation. Cardiovasc Diabetol 13:23CrossRef
10.
Mortensen A, Sorensen IK, Wilde C, Dragoni S, Mullerová D, Toussaint O, Zloch Z, Sgaragli G, Ovesná J (2008) Biological models for phytochemical research: from cell to human organism. Br J Nutr 99:ES118–ES126CrossRef
11.
Rideout TC, Harding SV, Jones PJH, Fan MZ (2008) Guar gum and similar soluble fibers in the regulation of cholesterol metabolism: current understandings and future research priorities. Vasc Health Risk Manag 4:1023–1033
12.
Nørskov NP, Hedemann MS, Lærke HN, Knudsen KEB (2013) Multicompartmental nontargeted LC–MS metabolomics: explorative study on the metabolic responses of rye fiber versus refined wheat fiber intake in plasma and urine of hypercholesterolemic pigs. J Proteome Res 12:2818–2832CrossRef
13.
Hanhineva K, Barri T, Kolehmainen M, Pekkinen J, Pihlajamäki J, Vesterbacka A, Solano-Aguilar G, Mykkänen H, Dragsted LO, Urban JF Jr et al (2013) Comparative nontargeted profiling of metabolic changes in tissues and biofluids in high-fat diet-fed Ossabaw pig. J Proteome Res 12:3980–3992CrossRef
14.
Ramprasath VR, Jones PJH, Buckley DD, Woollett LA, Heubi JE (2013) Effect of dietary sphingomyelin on absorption and fractional synthetic rate of cholesterol and serum lipid profile in humans. Lipids Health Dis 12:125CrossRef
15.
He W-S, Wang M-G, Pan X-X, Li J-J, Jia C-S, Zhang X-M, Feng B (2013) Role of plant stanol derivatives in the modulation of cholesterol metabolism and liver gene expression in mice. Food Chem 140:9–16CrossRef
16.
Shulaev V (2006) Metabolomics technology and bioinformatics. Brief Bioinform 7:128–139CrossRef
17.
Armitage EG, Rupérez FJ, Barbas C (2013) Metabolomics of diet-related diseases using mass spectrometry. Trac-Trends Anal Chem 52:61–73CrossRef
18.
Brennan L (2013) Metabolomics in nutrition research: current status and perspectives. Biochem Soc Trans 41:670–673CrossRef
19.
Kouskoumvekaki I, Panagiotou G (2011) Navigating the human metabolome for biomarker identification and design of pharmaceutical molecules. J Biomed Biotechnol Article ID 525497
20.
Ciborowski M, Ruperez JF, Martinez-Alcazar MP, Angulo S, Radziwon P, Olszanski R, Kloczko J, Barbas C (2010) Metabolomic approach with LC-MS reveals significant effect of pressure on diver’s plasma. J Proteome Res 9:4131–4137CrossRef
21.
Vallejo M, García A, Tunon J, Garcia-Martinez D, Angulo S, Martin-Ventura JL, Blanco-Colio LM, Almeida P, Egido J, Barbas C (2009) Plasma fingerprinting with GC–MS in acute coronary syndrome. Anal Bioanal Chem 394:1517–1524CrossRef
22.
Naz S, García A, Rusak M, Barbas C (2013) Method development and validation for rat serum fingerprinting with CE–MS: application to ventilator-induced-lung-injury study. Anal Bioanal Chem 405:4849–4858CrossRef
23.
Gika HG, Macpherson E, Theodoridis GA, Wilson ID (2008) Evaluation of the repeatability of ultra-performance liquid chromatography–TOF–MS for global metabolic profiling of human urine samples. J Chromatogr B 871:299–305CrossRef
24.
García A, Barbas C (2011) Gas chromatography–mass spectrometry (GC–MS)-based metabolomics. Methods Mol Biol 708:191–204CrossRef
25.
Westerhuis JA, Hoefsloot HCJ, Smit S, Vis DJ, Smilde AK, van Velzen EJJ, van Duijnhoven JPM, van Dorsten FA (2008) Assessment of PLSDA cross validation. Metabolomics 4:81–89CrossRef
26.
Llorach R, Garcia-Aloy M, Tulipani S, Vazquez-Fresno R, Andres-Lacueva C (2012) Nutrimetabolomic strategies to develop new biomarkers of intake and health effects. J Agric Food Chem 60:8797–8808CrossRef
27.
Rezzi S, Collino S, Goulet L, Martin F-P (2013) Metabonomic approaches to nutrient metabolism and future molecular nutrition. Trac-Trends Anal Chem 52:112–119CrossRef
28.
Tajima R, Kodama S, Hirata M, Horikawa C, Fujihara K, Yachi Y, Yoshizawa S, Iida KT, Sone H (2014) High cholesterol intake is associated with elevated risk of type 2 diabetes mellitus—a meta-analysis. Clin Nutr. doi:10.​1016/​j.​clnu.​2014.​03.​001
29.
Yasutake K, Kohjima M, Kotoh K, Nakashima M, Nakamuta M, Enjoji M (2014) Dietary habits and behaviors associated with nonalcoholic fatty liver disease. World J Gastroenterol 20:1756–1767CrossRef
30.
Gylling H (2014) Clinical utility of serum markers of cholesterol absorption and synthesis. Curr Opin Lipidol 25:207–212CrossRef
31.
McNamara DJ (2000) Dietary cholesterol and atherosclerosis. Biochim Biophys Acta Mol Cell Biol Lipids 1529:310–320CrossRef
32.
Staels B, Fonseca VA (2009) Bile acids and metabolic regulation: mechanisms and clinical responses to bile acid sequestration. Diabetes Care 32:S237–S245CrossRef
33.
Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K (2008) Targeting bile-acid signaling for metabolic diseases. Nat Rev Drug Discov 7:678–693CrossRef
34.
Reboul E, Goncalves A, Comera C, Bott R, Nowicki M, Landrier J-F, Jourdheuil-Rahmani D, Dufour C, Collet X, Borel P (2011) Vitamin D intestinal absorption is not a simple passive diffusion: evidences for involvement of cholesterol transporters. Mol Nutr Food Res 55:691–702CrossRef
35.
Miñambres I, Sánchez-Quesada JL, Sánchez-Hernández J, Rodríguez J, De Leiva A, Pérez A (2014) Vitamin D concentrations in familial combined hyperlipidemia: effects of lipid lowering treatment. Diabetol Metab Syndr 6: Article number 7
36.
Huang Y, Li X, Wang M, Ning H, Lima A, Li Y, Sun C (2013) Lipoprotein lipase links vitamin D, insulin resistance, and type 2 diabetes: a cross-sectional epidemiological study. Cardiovasc Diabetol 12: Article number 17
37.
Yin K, Agrawal DK (2014) Vitamin D and inflammatory diseases. J Inflamm Res 7:69–87
38.
D’Arrigo P, Servi S (2010) Synthesis of lysophospholipids. Molecules 15:1354–1377CrossRef
39.
Goyal J, Wang K, Liu M, Subbaiah PV (1997) Novel function of lecithin–cholesterol acyltransferase: hydrolysis of oxidized polar phospholipids generated during lipoprotein oxidation. J Biol Chem 272:16231–16239CrossRef
40.
Calabresi L, Simonelli S, Conca P, Busnach G, Cabibbe M, Gesualdo L, Gigante M, Penco S, Veglia F, Franceschini G (2014) Acquired lecithin:cholesterol acyltransferase deficiency as a major factor in lowering plasma HDL levels in chronic kidney disease. J Intern Med. doi:10.​1111/​joim.​12290
41.
Schaefer EJ, Anthanont P, Asztalos BF (2014) High-density lipoprotein metabolism, composition, function, and deficiency. Curr Opin Lipidol 25:194–199CrossRef
42.
Sekas G, Patton GM, Lincoln EC, Robins SJ (1985) Origin of plasma lysophosphatidylcholine: evidence for direct hepatic secretion in the rat. J Lab Clin Med 105:190–194
43.
Taylor LA, Arends J, Hodina AK, Unger K, Massing U (2007) Plasma lysophosphatidylcholine concentration is decreased in cancer patients with weight loss and activated inflammatory status. Lipids Health Dis 6:17CrossRef
44.
Spector AA (2009) Arachidonic acid cytochrome P450 epoxygenase pathway. J Lipid Res 50:S52–S56CrossRef
45.
Khanapure SP, Garvey DS, Janero DR, Letts LG (2007) Eicosanoids in inflammation: biosynthesis, pharmacology, and therapeutic frontiers. Curr Top Med Chem 7:311–340CrossRef
46.
Das UN (2013) Arachidonic acid and lipoxin A4 as possible endogenous anti-diabetic molecules. Prostaglandins Leukot Essent Fatty Acids 88:201–210CrossRef
47.
Shoji T, Kakiya R, Hayashi T, Tsujimoto Y, Sonoda M, Shima H, Mori K, Fukumoto S, Tahara H, Shioi A et al (2013) Serum n-3 and n-6 polyunsaturated fatty acid profile as an independent predictor of cardiovascular events in hemodialysis patients. Am J Kidney Dis 62:568–576CrossRef
48.
Astudillo AM, Balgoma D, Balboa MA, Balsinde J (2012) Dynamics of arachidonic acid mobilization by inflammatory cells. Biochim Biophys Acta Mol Cell Biol Lipids 1821:249–256CrossRef
49.
Nakamura MT, Nara TY (2004) Structure, function, and dietary regulation of Delta 6, Delta 5, and Delta 9 desaturases. Annu Rev Nutr 24:345–376CrossRef
50.
Kocsis K, Knapp L, Gellért L, Oláh G, Kis Z, Takakuwa H, Iwamori N, Ono E, Toldi J, Farkas T (2014) Acetyl-l-carnitine normalizes the impaired long-term potentiation and spine density in a rat model of global ischemia. Neurosciences 269:265–272CrossRef
51.
Luo T, Li J, Li L, Yang B, Liu C, Zheng Q, Jin B, Chen Z, Li K, Zhang X, Zhang J (2013) A study on the efficacy and safety assessment of propionyl-l-carnitine tablets in treatment of intermittent claudication. Thromb Res 132:427–432CrossRef
52.
Schooneman MG, Vaz FM, Houten SM, Soeters MR (2013) Acylcarnitines: reflecting or inflicting insulin resistance? Diabetes 62:1–8CrossRef
53.
Cardounel AJ, Cui H, Samouilov A, Johnson W, Kearns P, Tsai AL, Berka V, Zweier JL (2007) Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial NO production and vascular function. J Biol Chem 282:879–887CrossRef
54.
Cooke JP (2000) Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol 20:2032–2037CrossRef
55.
56.
Laleman W, Omasta A, van de Casteele M, Zeegers M, Vander Elst I, Van Landeghem L, Severi T, van Pelt J, Roskams T, Fevery J, Nevens F (2005) A role for asymmetric dimethylarginine in the pathophysiology of portal hypertension in rats with biliary cirrhosis. Hepatology 42:1382–1390CrossRef
57.
Baylis C (2006) Arginine, arginine analogs and nitric oxide production in chronic kidney disease. Nat Clin Pract Nephrol 2:209–220CrossRef
58.
Perticone F, Sciacqua A, Maio R, Perticone M, Galiano Leone G, Bruni R, Di Cello S, Pascale A, Talarico G, Greco L, Andreozzi F, Sesti G (2010) Endothelial dysfunction, ADMA and insulin resistance in essential hypertension. Int J Cardiol 142:236–241CrossRef
59.
Celik M, Cerrah S, Arabul M, Akalin A (2014) Relation of asymmetric dimethylarginine levels to macrovascular disease and inflammation markers in type 2 diabetic patients. J Diabetes Res Article number 139215
60.
Nishiyama Y, Otsuka T, Ueda M, Inagaki H, Muraga K, Abe A, Kawada T, Katayama Y (2014) Asymmetric dimethylarginine is related to the predicted stroke risk in middle-aged Japanese men. J Neurol Sci 338:87–91CrossRef
61.
Sheen J-M, Chen Y-C, Tain Y-L, Huang L-T (2014) Increased circulatory asymmetric dimethylarginine and multiple organ failure: bile duct ligation in rat as a model. Int J Mol Sci 15:3989–4006CrossRef
62.
Pawlak D, Tankiewicz A, Buczko W (2001) Kynurenine and its metabolites in the rat with experimental renal insufficiency. J Physio Pharmacol 52:755–766
63.
Pawlak K, Myśliwiec M, Pawlak D (2010) Kynurenine pathway—a new link between endothelial dysfunction and carotid atherosclerosis in chronic kidney disease patients. Adv Med Sci 55:196–203CrossRef
64.
Fan C-Y, Wang M-X, Ge C-X, Wang X, Li J-M, Kong L-D (2014) Betaine supplementation protects against high-fructose-induced renal injury in rats. J Nutr Biochem 25:353–362CrossRef
65.
Deminice R, Troncon F, Jordao AA (2013) Methionine and methylation balance: pathways for the production and removal of homocysteine. In: Deminice R, Rosa FR, Jordao AA, Snegursky A (eds) Methionine: biosynthesis, chemical structure and toxicity. Nova Science Publishers, Hauppauge, pp 9–25
66.
Tozzi MG, Camici M, Mascia L, Sgarrella F, Ipata PL (2006) Pentose phosphates in nucleoside interconversion and catabolism. FEBS J 273:1089–1101CrossRef
Metadata
Title
Multiplatform metabolomic fingerprinting as a tool for understanding hypercholesterolemia in Wistar rats
Authors
Diana González-Peña
Danuta Dudzik
Clara Colina-Coca
Begoña de Ancos
Antonia García
Coral Barbas
Concepción Sánchez-Moreno
Publication date
01-04-2016
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nutrition / Issue 3/2016
Print ISSN: 1436-6207
Electronic ISSN: 1436-6215
DOI
https://doi.org/10.1007/s00394-015-0914-1

Other articles of this Issue 3/2016

European Journal of Nutrition 3/2016 Go to the issue

Original Contribution

Mediatory effect of circulating vaspin on resting metabolic rate in obese individuals

Original Contribution

Green tea polyphenol extract in vivo attenuates inflammatory features of neutrophils from obese rats

Original Contribution

Medium-chain triglyceride ameliorates insulin resistance and inflammation in high fat diet-induced obese mice

Original Contribution

The effect of a cinnamon-, chromium- and magnesium-formulated honey on glycaemic control, weight loss and lipid parameters in type 2 diabetes: an open-label cross-over randomised controlled trial

Original Contribution

Examination of iodine status in the German population: an example for methodological pitfalls of the current approach of iodine status assessment

Original Contribution

Folic acid causes higher prevalence of detectable unmetabolized folic acid in serum than B-complex: a randomized trial
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits